UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000044977
Receipt number R000051245
Scientific Title Evaluation research about variations in autonomic nervous activity by test-food intake in a single dose
Date of disclosure of the study information 2022/07/31
Last modified on 2023/01/30 10:14:18

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation research about variations in autonomic nervous activity by test-food intake in a single dose

Acronym

Evaluation research about variations in autonomic nervous activity by test-food intake in a single dose

Scientific Title

Evaluation research about variations in autonomic nervous activity by test-food intake in a single dose

Scientific Title:Acronym

Evaluation research about variations in autonomic nervous activity by test-food intake in a single dose

Region

Japan


Condition

Condition

Healthy male/female adults

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

In order to evaluate changes in autonomic nervous activity by test-food intake in a single dose

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Heartbeat

Key secondary outcomes

1. Psychological questionnaire
2. Flavor-evaluating questionnaire
3. Body surface temperature


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Ingestion of the test liquid (200 mL) to the subjects within 5 min or 15 min.

Interventions/Control_2

Ingestion of the placebo (200 mL water) to the subjects within 5 min or 15 min.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

35 years-old >

Gender

Male and Female

Key inclusion criteria

(1) Healthy male/female subjects ranging in age from 20 to 34, at informed consent.
(2) Subjects having less than 25.0 kg/m2 of BMI.
(3) Subjects with no smoking (not less than one year).
(4) Subjects who can give informed consent to take part in this trial, after being provided with an explanation of the protocol detail.

Key exclusion criteria

(1) Subjects being under some kind of continuous medical treatment, including the test period.
(2) Subjects who have periodically used health-specific / functional / health foods including supplements, which might affect the autonomic nervous system, metabolism and sleep.
(3) Subjects with incompatible chest (e.g., thick bodyhair, pacemaker-fitting) for heartbeat measurements.
(4) Subjects with excessive alcohol intake (not less than 60 g/day/week).
(5) Subjects with extremely irregular eating habits, and subjects having an irregular life rhythm with irregular shift work or midnight one.
(6) At the moment of informed consent, subjects who are under the other clinical tests with some kind of medicine/food, or participated in those within four weeks after the current trial, or are planning to join those after the consent.
(7) Subjects who are under a large stress condition with some kind of life event, such as house-moving, transfer, bereavement, etc., within three months before the agreement for this trial and during the test period.
(8) Subjects with any difficulty in giving up drinking since the day before the scheduled date of this trial.
(9) Subjects with previous and/or current medical history of serious diseases in heart, liver, kidney and/or digestive organs.
(10) Subjects getting excessive exercise every day.
(11) Subjects with a serious symptom of premenstrual syndrome.
(12) Subjects having any difficulty in touching alcoholic drinks constitutionally.
(13) Pregnant, possibly pregnant, and lactating women.
(14) Subjects having some kind of drug and/or food allergy.
(15) Others who have been determined as ineligible for participation, judging from the principal/sub investigator's opinions.

Target sample size

40


Research contact person

Name of lead principal investigator

1st name Fumiko
Middle name
Last name Nakamura

Organization

CPCC Company Limited

Division name

Clinical Support Department

Zip code

101-0047

Address

4F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan

TEL

03-5297-3112

Email

cpcc-contact@cpcc.co.jp


Public contact

Name of contact person

1st name Masanori
Middle name
Last name Numa

Organization

CPCC Company Limited

Division name

Clinical Planning Department

Zip code

101-0047

Address

4F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan

TEL

03-5297-3112

Homepage URL


Email

cpcc-contact@cpcc.co.jp


Sponsor or person

Institute

CPCC Company Limited

Institute

Department

Personal name



Funding Source

Organization

Asahi Quality & Innovations, Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board of Chiyoda Paramedical Care Clinic

Address

2F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan

Tel

03-5297-5548

Email

IRB@cpcc.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 07 Month 31 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2021 Year 07 Month 20 Day

Date of IRB

2021 Year 07 Month 16 Day

Anticipated trial start date

2021 Year 07 Month 31 Day

Last follow-up date

2021 Year 09 Month 24 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 07 Month 28 Day

Last modified on

2023 Year 01 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051245


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name